Golden State Medical Supply, Inc.

Golden State Medical Supply, Inc., doing business as Golden State Medical Supply Inc., is a pharmaceutical manufacturer and distributor based in Camarillo, California, that supplies prescription medications and pharmaceutical products to federal healthcare systems as a prime contractor operating exclusively in full-and-open (unrestricted) procurements with no set-aside designations.

Golden State Medical Supply operates as a wholly owned subsidiary of Gsms Inc. and competes in the federal pharmaceutical supply market under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals). The company maintains an established portfolio of single-award Indefinite Delivery Contracts with the Department of Veterans Affairs National Acquisition Center and the Defense Logistics Agency Troop Support Medical covering a comprehensive range of essential medications—antidepressants, cardiovascular agents, anti-infectives, gastrointestinal medications, psychiatric medications, antiplatelet agents, and opioid-use-disorder treatment agents. Representative contracts include a $36.3 million Metformin HCL Immediate Release Tablets IDIQ awarded August 11, 2025, through August 10, 2026 with four one-year options; a $20.98 million Buprenorphine HCL/Naloxone HCL sublingual tablets contract awarded June 8, 2026; and a $17.7 million Ibuprofen Tablets IDIQ awarded November 23, 2025. The vendor also holds a $10.4 million Dimethyl Fumarate Delayed Release Capsules contract and a $12.7 million Dextroamphetamine-Amphetamine Extended Release capsules IDIQ with the Defense Logistics Agency, reflecting deep penetration in controlled-substance pharmaceutical supply. Beyond VA and DLA single-award vehicles, the vendor fills numerous delivery orders from the Federal Correctional Complex Victorville for inmate medical supplies and operates under standing contracts with the "Medical Supply Chain"—a federal agency designation spanning multiple healthcare delivery programs.

Customer concentration is heavily weighted toward the Department of Veterans Affairs and Department of Defense pharmacy networks. The Department of Veterans Affairs National Acquisition Center accounts for 312 awards (26.9% of the total award count) with $3.31 billion in combined potential value; the Defense Logistics Agency Troop Support Medical represents 650 awards (56% of total count) with $1.03 billion combined potential value. Together these two entities anchor 82.9% of the award count. However, the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 delivers the largest dollar concentration: 27 awards carrying $16.36 billion in combined potential value, substantially exceeding all other customers. This divergence between award count and dollar concentration signals that VA VISN 12 awards are strategically large single contracts whereas DLA awards are numerous smaller delivery orders. The vendor serves 35 distinct federal agencies across the portfolio.

The vendor's activity trajectory shows strong year-over-year growth. Awards increased from 83 in 2022 to 176 in 2024 and 218 in 2025, with 134 awards year-to-date in 2026. The combined potential value across all 1,157 awards totals $21.82 billion, though only $85.7 million has been obligated to date, reflecting the backlog typical of IDIQs awaiting delivery orders. The recompete cliff is minimal: only 2 awards with combined potential value of $27 thousand face ultimate completion within the next twenty-four months, indicating a stable contract portfolio with multi-year option periods extending visibility well beyond 2026. The vendor has operated continuously since at least 1990 according to the source data.

Golden State Medical Supply operates 100% as a prime contractor with no subcontract footprint in the source data. The company's primary vehicle positions include a 565-task-order IDC (SPE2D018D0004) valued at $467 thousand, an 89-task-order IDC (36E79720D0014) valued at $17.9 million, and a 54-task-order IDC (36E79720D0036) valued at $16.5 million, alongside 24 task orders on Federal Supply Schedule V797P5642X. The portfolio is overwhelmingly concentrated in pharmaceutical manufacturing: 1,093 of 1,157 awards (94.5%) fall under Pharmaceutical Preparation Manufacturing NAICS, with 43 awards in Medicinal and Botanical Manufacturing and 12 in Drugs and Druggist Sundries wholesale rounding out the remainder.